Privia Health Group, Inc. (PRVA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, optimistic guidance for 2025, and strategic growth in new markets. The Q&A section revealed positive analyst sentiment, with questions focusing on growth opportunities and market expansion. Despite some cautious language from management, the overall tone was positive. The company's strategic plan and guidance raise are expected to positively impact the stock price, especially given the small-cap nature of the company. The positive sentiment and strategic growth initiatives outweigh any concerns about cautious language or limited Q4 profitability growth.
Key Financial Performance
Implemented Provider Growth 13.1% year-over-year growth. This growth was supported by strong new provider signings and implementations across all markets.
Value-Based Attribution Growth 12.8% year-over-year growth. This was driven by new provider growth and entry into Arizona.
Practice Collections $940.4 million in Q3, a 27.1% increase year-over-year. Growth was attributed to implemented provider growth, strong value-based performance, and solid ambulatory utilization trends.
Adjusted EBITDA $38.2 million in Q3, a 61.6% increase year-over-year. The EBITDA margin as a percentage of care margin expanded by 720 basis points to 30.5%. This was due to better-than-expected results across the value-based care book, generating significant operating leverage.
Aggregate Savings Rate in Medicare Shared Savings Program (MSSP) 9.4% in 2024, up from 8.2% in 2023. This increase demonstrates success in increasing savings and profitability.
Total Shared Savings $234.1 million in 2024, a 32.6% increase year-over-year. This reflects the success in adding value-based and downside risk lives and contracts.
Gross Shared Savings (Privia's Share) $160.1 million in 2024, a 36% increase year-over-year. This amount is recognized in practice collections and GAAP revenue.
Pro Forma Cash $409.9 million at the end of Q3 2025, with no debt. This includes the deployment of $100 million for the ACO business acquisition and net cash received from CMS for the 2024 MSSP performance year.
Year-to-Date Pro Forma Free Cash Flow $104.4 million, excluding cash deployed for business development transactions. This reflects strong free cash flow generation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Acquisition of ACO business: Privia Health agreed to acquire an accountable care organization business from Evolent Health for $100 million in cash, plus an earn-out of up to $13 million based on 2025 MSSP performance. This acquisition will add over 120,000 value-based care attributed lives across existing and new states.
Expansion into Arizona: Privia Health entered the Arizona market, contributing to a 13% increase in total attributed lives year-over-year.
National footprint: Privia Health now operates in 15 states and D.C., with 5,250 implemented providers caring for over 5.6 million patients in 1,340 care center locations.
Value-based care performance: Privia managed over $2.5 billion in medical spend in 2024, achieving a 9.4% aggregate savings rate, up from 8.2% in 2023. Total shared savings increased 32.6% to $234.1 million, with Privia's gross shared savings at $160.1 million, a 36% increase over 2023.
Provider and patient growth: Implemented provider growth of 13.1% and value-based attribution growth of 12.8% year-over-year supported a 27.1% increase in practice collections in Q3 2025.
Financial performance: Adjusted EBITDA increased 61.6% year-over-year to $38.2 million in Q3 2025, with EBITDA margin expanding 720 basis points to 30.5%. Practice collections for the first 9 months of 2025 grew 19.6% to $2.6 billion.
Focus on value-based care: Privia Health remains focused on generating positive contribution margin in value-based contracts, managing risk, and implementing clinical and operational enhancements.
Financial flexibility: Pro forma cash at the end of Q3 2025 was $409.9 million with no debt, positioning the company for future opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The acquisition of the accountable care organization business from Evolent Health is pending regulatory approvals, which could delay or impact the transaction's completion.
Dependence on Value-Based Contracts: The company is highly focused on generating positive contribution margins in value-based contracts, which requires effective risk management and operational enhancements. Failure in these areas could impact profitability.
Market Environment: While the company has demonstrated performance across various market environments, any significant changes in economic or healthcare conditions could pose challenges.
Integration of Acquired Business: The integration of the newly acquired ACO business into Privia's platform could present operational challenges and risks, especially in aligning new providers with the company's technology and service platform.
Financial Projections: The financial results reported are preliminary and subject to change, which could impact investor confidence and strategic planning.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Guidance Update: Privia Health raised its 2025 outlook above the high end of previous ranges. Implemented providers are expected to increase 11.2% year-over-year to reach 5,325 by year-end. Attributed lives growth is expected to be approximately 12.5%. Practice collections are projected to grow 17.1% and care margin 13.2% at their respective midpoints. Adjusted EBITDA growth is expected to be 32% at the midpoint, with more than 80% of full-year 2025 adjusted EBITDA converting to free cash flow.
ACO Business Acquisition: Privia Health agreed to acquire an accountable care organization business from Evolent Health for $100 million in cash, plus an earn-out of up to $13 million based on 2025 MSSP performance. This acquisition will add over 120,000 value-based care attributed lives and is expected to positively contribute to adjusted EBITDA in 2026.
2026 Projections: The company expects continued success in 2026, supported by strong new provider signings and implementations across all markets. The ACO business acquisition is anticipated to expand total attributed lives to more than 1.5 million, contributing to scale and profitability.
Value-Based Care Growth: Privia Health plans to focus on generating positive contribution margins in value-based contracts by pursuing attribution growth, managing risk, and implementing clinical and operational enhancements in its medical groups.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the company plan to guide MSSP performance in the future given the strong results for 2024?
A:The company plans to remain consistent with its approach over the past 7-8 years. They will factor in data from CMS, attribution changes, program structure, and fee rates. The outperformance in 2024 will be factored into the baseline for future planning, and guidance will be updated annually based on prior year results and current estimates.
Q:What is the outlook for the core business in Q4 and the $130 million EBITDA target for 2026?
A:The company sees strong trends continuing into Q4 but does not provide quarterly guidance, focusing instead on annual results. They are targeting $120 million for 2024 and aim for 20% growth into 2025. The momentum positions them well for a strong 2026.
Q:What factors influenced the strong fee-for-service growth and practice collections per provider?
A:The growth was broad-based, driven by utilization trends, value-based book performance, and new markets like Arizona and Indiana. The momentum across same-store growth, new providers, and new markets contributed to the results.
Q:What are the synergy opportunities with the Evolent Health ACO and the physician base?
A:The company sees opportunities to enhance savings rates and cross-sell in existing states. They plan to integrate practices into their medical groups and expand into six new states. Improving ACO performance and finding anchor providers in new states are key priorities.
Q:What are the moving pieces in the capitated business this quarter, including revenue step-up and membership changes?
A:The capitated book is small (20,000-22,000 lives) and performed well due to attribution, risk adjustment, and cost-side performance. There was some retroactivity back to January 1, and Q3 is expected to be the high mark for the year.
Q:How does the Evolent acquisition change the cadence of new market growth and the appetite for incremental M&A?
A:The acquisition adds six new states but does not change the cadence of implementing the full model in new states. The company remains disciplined on price and continues to pursue opportunities aggressively, leveraging market dislocation.
Q:How does the shift from ACO REACH to MSSP by other companies impact the landscape and M&A opportunities?
A:The shift creates opportunities as some entities struggle to scale or become profitable. The company sees potential to acquire entities or physicians at reasonable prices, as demonstrated by the Evolent transaction.
Q:How are payer relationships evolving, and are there any dramatic changes in negotiations?
A:The company maintains ongoing discussions with payers at both state and national levels. Strong results and a differentiated value proposition help in negotiating incremental gains towards value-based care.
Q:What factors contributed to the MA CAP performance this quarter, and is there room to grow MA lives?
A:Performance was driven by prudent accruals and strong cost-side management. The company aims to grow MA lives through same-store growth, new providers, and new contracts in existing and new states.
Q:Are there any notable utilization trends or disruptions in payer classes?
A:Elevated utilization trends continue across the board, particularly in ambulatory settings. The company does not expect significant changes in Q4 but remains cautious about potential shifts in patient mix.
Q:How have Privia's ancillary capabilities evolved with provider growth and new markets?
A:The company focuses on building density in states to expand into labs, pharmacy benefits, ASCs, and clinical research. These efforts aim to control costs and monetize the platform effectively.
Q:What is included in the Evolent Care Partners acquisition, and does it include the Blue Cross Blue Shield of North Carolina contract?
A:The acquisition includes all contracts, including commercial and MA, as well as the MSSP business. Specific contract details are not disclosed, but the company aims to perform as expected or better.
Q:Why does the implied Q4 guidance show limited profitability growth and margin compression?
A:The company is being prudent in its guidance despite strong year-to-date performance. IMS will contribute to profitability starting in Q4, and bonus accruals are already factored into the guidance.
Q:What is the impact of the New Big Beautiful Bill Law on Privia's Medicaid book?
A:The law is not expected to have a significant impact as Medicaid is a small part of the company's collections. Patient mix changes are not anticipated to affect primary care demand significantly.
Q:What are the growth opportunities in ancillary services like ASCs?
A:The company sees opportunities in outpatient surgeries, ASCs, and managing total cost of care as they build density in states. They aim to expand selectively in areas like cardiology, pulmonology, and orthopedics.
Q:What are the odds of a V29 in MA, and what would make the company more comfortable taking more risk in MA?
A:The company focuses on shared risk models and alignment of interests between payers, providers, and Privia. They remain cautious about capitation and aim for sustainable contracts that align incentives.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about quarterly guidance, specific contract details (e.g., Blue Cross Blue Shield of North Carolina), and the exact impact of retroactive adjustments on MA CAP performance. They also used cautious language when discussing potential changes in utilization trends and the impact of the New Big Beautiful Bill Law.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACO acquisition
ACO provider
Advantage arrangement
Arizona Commercial
Borchert SVP
Communications Vice
DC value
Evolent Health
Health Results
Health cash
Health result
Instructions Borchert
MSSP Medicare
Program provider
Providers patient
Results Conference
Today highlight
ability type
acquisition life
approach value
approval footprint
arrangement transaction
aspect momentum
book confidence
care Evolent
care book
care strength
cash earn
confidence scale
contract ACO
earn value
end approval
enhancement group
footprint Providers
government payer
group technology
implementation market
life contribution
life state
momentum success
partner result
platform transaction
point confidence
profitability contract
provider entry
PRVA Transcript
Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary and Q&A reveal strong financial performance, strategic growth in Medicaid and Medicare Advantage, and disciplined capital deployment plans. Despite maintaining guidance, management's focus on AI and value-based care, along with a promising outlook on partnerships and MA growth, are positive indicators. The market cap suggests moderate sensitivity to news, leading to a prediction of a positive stock price movement of 2% to 8%.
Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong financial metrics, optimistic guidance, and strategic acquisitions, like the Evolent ACO, likely to enhance future profitability. The company’s strategy to deploy capital for growth, coupled with raised guidance, indicates positive market sentiment. Despite some management evasiveness on specifics, the overall tone is confident, suggesting a stock price increase. Given the market cap of $2 billion, the reaction is expected to be moderately positive.
Privia Health Group, Inc. (PRVA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, optimistic guidance for 2025, and strategic growth in new markets. The Q&A section revealed positive analyst sentiment, with questions focusing on growth opportunities and market expansion. Despite some cautious language from management, the overall tone was positive. The company's strategic plan and guidance raise are expected to positively impact the stock price, especially given the small-cap nature of the company. The positive sentiment and strategic growth initiatives outweigh any concerns about cautious language or limited Q4 profitability growth.
Privia Health Group, Inc. (PRVA) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call summary and Q&A highlight strong financial performance, strategic growth, and optimistic guidance. Key positive factors include broad-based growth, effective risk management, and favorable regulatory impacts. The IMS integration is progressing well, and the company is raising its 2025 revenue outlook. Despite increased G&A expenses, the company's balanced model and platform enhancements provide significant opportunities. The market cap indicates a moderate reaction, leading to a 'Positive' prediction for stock price movement in the next two weeks.
PRVA Slides
Privia Health Q1 2026 slides show operational strength, earnings disappoint2026-05-07
Privia Health Q4 2025 slides: EBITDA surges 39%, guidance strong2026-02-26
Privia Health Q2 2025 slides: Strong growth and raised guidance, but shares plunge2025-08-07
Privia Health Q1 2025 slides: Strong growth and margin expansion fuel raised guidance2025-05-08
PRVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
